-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 3,126 Shares of Stock
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 3,126 Shares of Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 3,126 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $19.64, for a total value of $61,394.64. Following the completion of the sale, the insider now owns 97,472 shares of the company's stock, valued at $1,914,350.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Crinetics Pharmaceuticals Price Performance
Crinetics Pharmaceuticals stock traded down $0.61 during midday trading on Wednesday, reaching $18.44. The company's stock had a trading volume of 199,486 shares, compared to its average volume of 285,811. The stock's 50-day simple moving average is $20.33 and its 200-day simple moving average is $20.11. Crinetics Pharmaceuticals, Inc. has a 52-week low of $15.91 and a 52-week high of $28.95. The stock has a market capitalization of $991.21 million, a P/E ratio of -6.24 and a beta of 1.10.
Get Crinetics Pharmaceuticals alerts:Institutional Investors Weigh In On Crinetics Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC raised its stake in Crinetics Pharmaceuticals by 10.7% in the second quarter. Driehaus Capital Management LLC now owns 5,474,459 shares of the company's stock valued at $102,099,000 after buying an additional 530,446 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 0.6% in the first quarter. BlackRock Inc. now owns 3,296,780 shares of the company's stock valued at $72,365,000 after purchasing an additional 20,610 shares during the period. Bain Capital Life Sciences Investors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 13.6% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,305,558 shares of the company's stock valued at $42,999,000 after purchasing an additional 275,857 shares during the period. State Street Corp increased its holdings in shares of Crinetics Pharmaceuticals by 3.5% in the second quarter. State Street Corp now owns 1,760,845 shares of the company's stock valued at $32,840,000 after purchasing an additional 60,166 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Crinetics Pharmaceuticals in the first quarter valued at about $31,055,000. 94.42% of the stock is currently owned by hedge funds and other institutional investors.
Crinetics Pharmaceuticals Company Profile
(Get Rating)Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Articles
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Hot Potato: Lamb Weston Stock Confirms a Top
- Too Soon: 3 Reasons to Wait on DocuSign Stock
- Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 3,126 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $19.64, for a total value of $61,394.64. Following the completion of the sale, the insider now owns 97,472 shares of the company's stock, valued at $1,914,350.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Crinetics制药公司(纳斯达克代码:CRNX-GET评级)内部人士斯蒂芬·F·贝茨在一笔日期为10月3日星期一的交易中出售了3,126股该股。这些股票的平均价格为19.64美元,总价值为61,394.64美元。出售完成后,这位内部人士现在拥有该公司97,472股股票,价值1,914,350.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接.
Crinetics Pharmaceuticals Price Performance
Crinetics药品价格表现
Crinetics Pharmaceuticals stock traded down $0.61 during midday trading on Wednesday, reaching $18.44. The company's stock had a trading volume of 199,486 shares, compared to its average volume of 285,811. The stock's 50-day simple moving average is $20.33 and its 200-day simple moving average is $20.11. Crinetics Pharmaceuticals, Inc. has a 52-week low of $15.91 and a 52-week high of $28.95. The stock has a market capitalization of $991.21 million, a P/E ratio of -6.24 and a beta of 1.10.
周三午盘交易中,Crinetics PharmPharmticals股价下跌0.61美元,至18.44美元。该公司股票的成交量为199,486股,而其平均成交量为285,811股。该股的50日简单移动均线切入位为20.33美元,200日简单移动均线切入位为20.11美元。Crinetics PharmPharmticals,Inc.的52周低点为15.91美元,52周高位为28.95美元。该股市值为9.9121亿美元,市盈率为-6.24,贝塔系数为1.10。
Institutional Investors Weigh In On Crinetics Pharmaceuticals
机构投资者看好Crinetics制药公司
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC raised its stake in Crinetics Pharmaceuticals by 10.7% in the second quarter. Driehaus Capital Management LLC now owns 5,474,459 shares of the company's stock valued at $102,099,000 after buying an additional 530,446 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 0.6% in the first quarter. BlackRock Inc. now owns 3,296,780 shares of the company's stock valued at $72,365,000 after purchasing an additional 20,610 shares during the period. Bain Capital Life Sciences Investors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 13.6% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,305,558 shares of the company's stock valued at $42,999,000 after purchasing an additional 275,857 shares during the period. State Street Corp increased its holdings in shares of Crinetics Pharmaceuticals by 3.5% in the second quarter. State Street Corp now owns 1,760,845 shares of the company's stock valued at $32,840,000 after purchasing an additional 60,166 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Crinetics Pharmaceuticals in the first quarter valued at about $31,055,000. 94.42% of the stock is currently owned by hedge funds and other institutional investors.
一些对冲基金和其他机构投资者最近增持或减持了该业务的股份。Driehaus Capital Management LLC在第二季度将其在Crinetics PharmPharmticals的持股增加了10.7%。Driehaus Capital Management LLC在上个季度额外购买了530,446股后,现在拥有5,474,459股该公司股票,价值102,099,000美元。贝莱德股份有限公司在第一季度增持了Crinetics PharmPharmticals的股票0.6%。贝莱德股份有限公司在此期间增持了20,610股,目前持有该公司3,296,780股股票,价值72,365,000美元。贝恩资本生命科学投资者有限责任公司在第二季度增持了13.6%的Crinetics PharmPharmticals股票。贝恩资本生命科学投资者有限责任公司现在拥有该公司2,305,558股股票,价值42,999,000美元,在此期间又购买了275,857股。道富集团第二季度增持Crinetics PharmPharmticals股票3.5%。道富银行目前持有1,760,845股该公司股票,价值32,840,000美元,在此期间又购买了60,166股。最后,弗雷泽生命科学管理公司在第一季度收购了Crinetics制药公司的新股票,价值约31,055,000美元。94.42%的股票目前由对冲基金和其他机构投资者持有。
Crinetics Pharmaceuticals Company Profile
Crinetics制药公司简介
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Crinetics制药公司是一家临床阶段制药公司,专注于罕见内分泌疾病和内分泌相关肿瘤治疗药物的发现、开发和商业化。它的主要候选产品是Paltusotine,这是一种口服选择性非肽生长抑素受体2型激动剂,已经完成了治疗肢端肥大症的第三阶段临床试验,以及治疗类癌综合征和无功能神经内分泌肿瘤(NETS)的第二阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Hot Potato: Lamb Weston Stock Confirms a Top
- Too Soon: 3 Reasons to Wait on DocuSign Stock
- Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
- 免费获取StockNews.com的Crinetics PharmPharmticals研究报告(CRNX)
- 辣土豆:韦斯顿羊肉库存涨幅居前
- 太快:等待DocuSign股票的三个理由
- 礼仪援助唱出了投资者不愿听到的熟悉曲调
- 不要放弃这些第三季度的失败者
- 一个伟大的养老金计划的剖析
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Crinetics PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Crinetics制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧